News

The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will be conducted by investigators at the Center

The first collaboration, with Harvard University, is based upon a new pain-drug-delivery technique that targets pain-sensing neurons without affecting motor neurons. Under the terms of the agreement, Endo

“During the quarter we prepared to initiate our two randomized Phase II trials for nimotuzumab, which concentrate on two forms of cancer typically treated with radiation-containing regimens. These

The company has reported data from the first of three cohorts in an ascending multiple dose study of MSI-1436 (Study 102). Data from cohort 1, in which eight

Fourth Quarter Financial Highlights Consolidated net revenues increase by 33.9% to EUR68.5 million (+32.9% at constant exchange rates); EBITDA grow to EUR24.2 million, up 62.0% compared with the

The agreement resolves litigation that was pending in the US District Court of Texas with respect to certain Ethicon products. Ethicon is a subsidiary of Johnson & Johnson.

Mr Walker was most recently the chairman and CEO of Novacea, which merged with Transcept Pharmaceuticals in January 2009. Mr Walker currently serves on the board of directors

These positions were eliminated after Panacos sold bevirimat, and the company has refocused its efforts on its early stage programs. Dr McCallister has served in this capacity since

According to the company, results of initial studies outline the device’s ability to significantly improve drug delivery to mucous membranes such as those in the nose, intestine, eyes,